Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—

today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities that strengthen its ability to drive stenoparib’s clinical development while expanding external partnership opportunities.

Allarity Therapeutics was established on its proprietary patient selection technology—the Drug Response Predictor (DRP®). DRP® allows Allarity to assess a patient’s tumor tissue for the gene expression changes that indicate the patient’s tumor is either more or less likely to respond to a given cancer therapy. DRP® tests have been successfully developed for dozens of cancer therapies. Most notably, DRP® has been developed for Allarity’s lead asset, stenoparib, and has been deployed in the clinic to pre-select patients for stenoparib-based therapy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.